We provide the latest news
from the world of economics and finance
(RTTNews) - Sana Biotechnology, Inc. (SANA) said on Thursday that it has priced its underwritten upsized public offering of 17,272,728 shares at $5.50 per share and, in lieu of shares to certain investors, pre-funded warrants to purchase 12,727,272 shares at $5.4999 per pre-funded warrant.
Proceeds from the offering, to be closed on or about February 12, are expected to be at around $165 million.
The company has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares.
Sana will sell all of the shares and pre-funded warrants.
Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC, and BofA Securities are acting as joint book-running managers for the offering.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.